GlassScriptPhysician profile
Priyanka Agarwal
NPI 1326466145
$1,793.34
in general payments reported to CMS, 2019-2025
24 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $108 · 2021: $220 · 2022: $373 · 2023: $233 · 2024: $335 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070 · Education: $21.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.27 |
| Education | $21.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.94 | 2023-2025 | Jardiance |
| Zimmer Biomet Holdings, INC. | $205.51 | 2021 | |
| Lilly USA, LLC | $192.28 | 2022-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $122.60 | 2020-2021 | |
| Amphastar Pharmaceuticals, INC. | $114.19 | 2024-2025 | |
| Abbott Laboratories | $93.20 | 2024-2025 | Freestyle Libre 3, Id Now Instrument |
| Xeris Pharmaceuticals, INC. | $91.08 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $90.16 | 2024-2025 | |
| Dexcom, INC. | $69.10 | 2022-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $64.54 | 2022 | |
| Corcept Therapeutics | $63.24 | 2022 | |
| Soleno Therapeutics, INC. | $59.41 | 2025 | Vykat Xr |
| Mannkind Corporation | $55.89 | 2022-2023 | Afrezza |
| Madrigal Pharmaceuticals | $42.63 | 2025 | Rezdiffra |
| Mckesson Corporation | $42.49 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuity Medical INC | $36.01 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Ascendis Pharma Endocrinology INC | $29.65 | 2025 | Yorvipath |
| Insulet Corporation | $29.35 | 2023 | Omnipod |
| Sequel Med Tech, LLC | $27.28 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $26.89 | 2025 | |
| Cranial Technologies, INC | $17.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.93 | 2023 | |
| Abbvie INC. | $14.76 | 2023 | Synthroid |
| Medtronic, INC. | $14.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priyanka Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.